Marshall Wace
CVAC

Marshall Wace’s CureVac CVAC Stock Holding History

Marshall Wace’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,610
Closed -$44.3K – 2620
2024
Q1 		$44.3K Sell
14,610
-74,490
-84% -$261K ﹤0.01% 2351
2023
Q4 		$375K Sell
89,100
-27,791
-24% -$151K ﹤0.01% 1817
2023
Q3 		$798K Buy
116,891
+35,774
+44% +$316K ﹤0.01% 1571
2023
Q2 		$845K Sell
81,117
-4,044
-5% -$36.2K ﹤0.01% 1789
2023
Q1 		$594K Sell
85,161
-510,101
-86% -$4.45M ﹤0.01% 2028
2022
Q4 		$3.59M Buy
595,262
+261,443
+78% +$1.93M 0.01% 1405
2022
Q3 		$2.63M Buy
333,819
+1,758
+0.5% +$20.5K 0.01% 1835
2022
Q2 		$4.52M Buy
332,061
+160,279
+93% +$2.65M 0.01% 1420
2022
Q1 		$3.37M Buy
+171,782
New +$3.43M 0.01% 1710
2021
Q2 		– Sell
-39,415
Closed -$3.6M – 2719
2021
Q1 		$3.6M Buy
+39,415
New +$3.82M 0.02% 1018
2020
Q4 		– Sell
-12,335
Closed -$574K – 1925
2020
Q3 		$574K Buy
+12,335
New +$688K ﹤0.01% 1195

Other funds holding CVAC

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's CVAC Position: Q2 2024 in Review

Marshall Wace sold out of CureVac (CVAC) in Q2 2024, closing a stake of 14,610 shares — an estimated $44.3K sold.

Marshall Wace first reported a position in CVAC in Q3 2020 and held it in 11 quarters. The position peaked at $4.52M in Q2 2022. 87 funds tracked by Wall St. Rank hold CVAC as of Q2 2024.

  • Marshall Wace reported no remaining CureVac position as of Q2 2024 after selling out during the quarter.
  • Marshall Wace sold 14,610 CureVac shares in Q2 2024, an estimated $44.3K.
  • Marshall Wace first reported a position in CureVac in Q3 2020 and held it in 11 quarters.
  • Marshall Wace's CureVac position peaked at $4.52M in Q2 2022.
  • 87 funds tracked by Wall St. Rank held CureVac as of Q2 2024.

Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.